Activation of Toll-like receptor (TLR) signaling by microbial signatures is critical to the induction of immune responses. Such responses demand tight regulation. RP105 is a TLR homolog thought to be mostly B cell specific, lacking a signaling domain. We report here that RP105 expression was wide, directly mirroring that of TLR4 on antigen-presenting cells. Moreover, RP105 was a specific inhibitor of TLR4 signaling in HEK 293 cells, a function conferred by its extracellular domain. Notably, RP105 and its helper molecule, MD-1, interacted directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligand. Finally, RP105 regulated TLR4 signaling in dendritic cells as well as endotoxin responses in vivo. Thus, our results identify RP105 as a physiological negative regulator of TLR4 responses.
The field of innate immunity has undergone a renaissance fueled mainly by the molecular identification of critical receptors and signaling pathways involved in pathogen recognition. Study of the Toll-like receptor (TLR) family has led the way. Activation of TLR signaling by conserved microbial molecular 'signatures' promotes the induction of both innate and adaptive immune responses 1, 2 . It has long been apparent that such immune responses need to be kept under tight control. Responses that are delayed or of insufficient vigor can lead to a failure to control infection. However, excessive or inappropriate inflammation can be harmful or even fatal. The hyperinflammatory responses that characterize sepsis provide a paradigmatic example, as do the more localized inappropriate inflammatory processes leading to inflammatory bowel disease and arthritis. [3] [4] [5] Mammalian TLRs are characterized structurally by an extracellular leucine-rich repeat domain, a conserved pattern of juxtamembrane cysteine residues, and an intracytoplasmic signaling domain (Tollinterleukin 1 (IL-1) receptor) that is highly conserved across the TLRs as well as the receptors for IL-1 and IL-18 (ref. 2) . The TLR-like molecule RP105 was originally cloned as a B cell-specific molecule able to drive B cell proliferation 6, 7 . Like TLRs, RP105 has a conserved extracellular leucine-rich repeat domain and a TLR-like pattern of juxtamembrane cysteines [6] [7] [8] [9] [10] . Unlike the TLRs, however, RP105 lacks a Toll-IL-1 receptor domain, containing a mere 6-11 intracytoplasmic amino acids (depending on the prediction algorithm used). In parallel with TLR4, whose surface expression and signaling depend on coexpression of the secreted extracellular protein MD-2, surface expression of RP105 is dependent on coexpression of the MD-2 homolog MD-1 (refs. 11-14) .
Here we show that RP105 is a specific homolog of TLR4. We further show that RP105 is not B cell specific as originally proposed: RP105 protein expression directly mirrored that of TLR4 on antigen-presenting cells. In Toll and TLR4, mutation of the conserved juxtamembrane cysteine residues or substantial deletion of the extracellular portion results in a constitutively active molecule [15] [16] [17] . This suggests that Toll and/or TLR activation is normally restrained through extracellular protein-protein interactions, probably through the leucine-rich repeat domain. In contrast, deletions or mutations in the Toll-IL-1 receptor domain of Toll and/or TLRs can yield inactive or dominant negative molecules 15, 18, 19 . Thus, RP105 has the apparent structure of an inhibitory TLR4. These considerations led us to the hypothesis that RP105 is a physiological regulator of TLR4 signaling. Here, RP105 was a specific inhibitor of TLR4 signaling in HEK 293 cells, a function conferred by its extracellular domain. Mechanistically, the RP105-MD-1 complex interacted directly with TLR4-MD-2, inhibiting the ability of this lipopolysaccharide (LPS) signaling complex to bind LPS. Finally, RP105 was a physiological regulator of TLR4 signaling in primary dendritic cells and of responses to endotoxin in vivo.
RESULTS

RP105 expression mirrors that of TLR4
Phylogenetic analysis of the TLR family has shown that it includes five subfamilies: TLR4; TLR3; TLR5; TLR7, TLR8 and TLR9; and TLR2, TLR1, TLR6 and TLR10 (ref. 2) . Similar analytic techniques unequivocally placed RP105 in the TLR4 subfamily ( Supplementary Fig. 1 online). The domain structure of the 641-amino acid mature RP105 protein has been reported 7, 9, 10, 13 . The extracellular portion of this type I transmembrane protein contains 22 leucine-rich repeats (with repeats 7-10 being atypical), along with a pattern of juxtamembrane cysteines that is conserved among the Toll and TLR families. Prediction algorithms disagree on the C-terminal boundary of the transmembrane domain. Although the 6-to 11-amino acid intracellular domain of RP105 contains 1-2 tyrosine residues, it is devoid of conserved motifs that would suggest potential sites for phosphorylation.
RP105 has been reported as a B cell-specific molecule in mice 7 . Furthermore, despite the fact that RP105 is expressed at the mRNA level in primary human myeloid cells [8] [9] [10] , the only published study to our knowledge of RP105 protein expression in such cells (by immunoblot) reportedly had negative results 10 . We examined RP105 expression by flow cytometry in human and mouse monocytic cells. In neither species was RP105 expression limited to B cells. In humans, RP105 was also expressed by monocytes as well as myeloid dendritic cells (DCs; Fig. 1a-c) , cells that express considerably more TLR4 than do B cells 20 (data not shown). RP105 was not expressed by human plasmacytoid DCs (Fig. 1d) , cells that also fail to express TLR4 (refs. 20-22 and data not shown).
Similarly, flow cytometry showed that mice expressed RP105 on resident peritoneal macrophages and splenic DC subsets as well as bone marrow-derived DCs (Fig. 2) . To confirm the specificity of the monoclonal antibody used here, we examined RP105-deficient mice alongside wild-type mice; there was no RP105 staining in B cells, macrophages or DCs from RP105 knockout mice (data not shown). Furthermore, to rule out any potential artifacts (from, for example, a soluble isoform of RP105), we analyzed bone marrow-derived DCs by RT-PCR to confirm endogenous RP105 expression by such cells (data not shown). Unlike those found in human peripheral blood, essentially all of the splenic plasmacytoid DCs from mice treated with Flt3 ligand, a growth and differentiation factor for DCs, expressed both RP105 and TLR4 (Fig. 2f and data not shown) . Thus, RP105 is not B cell specific and its expression directly mirrors that of TLR4 on human and mouse macrophages and DCs.
RP105 suppresses TLR4 signaling in HEK 293 cells HEK 293 cells lack expression of endogenous TLR2, TLR4, TLR9, MD-2 and CD14 (ref. 23 ) as well as RP105 and MD-1 (data not shown). Their TLR signaling machinery is fully functional, however 23 . As a result, HEK 293 cells are used extensively for the in vitro analysis of TLR function 23, 24 . Given the homology of RP105 to TLR4, we first assessed whether RP105-MD-1 could act as a signaling receptor for LPS in HEK 293 cells. We used HEK 293 cells that stably express CD14 and transiently transfected them with cDNA encoding MD-1, MD-2, RP105 and/or TLR4. Although TLR4-MD-2 expression conferred LPS sensitivity, with resultant LPS-driven IL-8 production, RP105-MD-1 expression did not (Fig. 3a) . These data are consistent with published data generated using Ba/F3 cells: even in B cell lines, no direct involvement of RP105 as a signaling receptor for LPS has been shown 25 . We confirmed that in vitro overexpression of TLR4-MD-2 in HEK 293 cells led to an increase in baseline IL-8 production in the absence of stimulation (Fig. 3a) .
We also examined the effects of RP105-MD-1 expression on LPSdriven TLR4 signaling. Notably, RP105 expression inhibited TLR4-driven IL-8 production by HEK 293 cells in a dose-dependent way (Fig. 3b) . Furthermore, RP105-mediated inhibition of LPS-driven IL-8 production was associated with inhibition of LPS-driven transactivation of the transcription factor NF-kB (Fig. 3c) , suggesting We next examined the specificity of RP105-mediated suppression of proinflammatory signaling. RP105 did not inhibit IL-1-or TLR2-driven IL-8 production (Fig. 4) . Indeed, RP105 overexpression led to variable augmentation of TLR2-mediated IL-8 production in some experiments (Fig. 4b) . Thus, RP105-mediated suppression shows specificity among the TLR-IL-1 receptor family.
We also formally examined the necessity for MD-1 expression in this system. In the absence of MD-1 coexpression, RP105 did not inhibit TLR4 signaling ( Supplementary Fig. 2 online) . Consistent with a published report that MD-1 expression is required for surface expression of RP105 (ref. 13 ), we did not detect RP105 on cells in the absence of MD-1 coexpression ( Supplementary Fig. 2 online) . Thus, RP105-MD-1 is a specific inhibitor of TLR4 signaling in HEK 293 cells.
Suppression by the RP105 extracellular domain Antibodies to RP105 can induce signaling events and proliferation in B cells, although there is no evidence that RP105 signals directly 6, 10, [25] [26] [27] . Use of such antibodies in human primary monocytes did not induce a measurable signal (cytokine production; data not shown), an observation that suggested that the mechanism of suppressive action of RP105 might be independent of any putative signaling through its intracellular tail. Consistent with that, RP105 did not inhibit NF-kB transactivation induced through the overexpression of TLR4 signaling molecules 28 ( Supplementary Fig. 3 online). We therefore constructed a soluble mutant of RP105 lacking the transmembrane and intracellular domains. Initial analysis by immunoprecipitation showed that the RP105 extracellular domain protein was secreted into the medium of transfected cells (data not shown). Mechanistic analysis showed that coexpression of MD-1 and the extracellular portion of RP105 was sufficient to effect RP105-mediated suppression of TLR4 signaling (Fig. 5a ). Identical to findings with the full-length construct, suppression of signaling by the extracellular domain of RP105 had considerable specificity, failing to inhibit TLR2 or IL-1 receptor signaling in HEK 293 cells (Fig. 5b,c) . Thus, inhibition of TLR4 signaling is mediated by the extracellular domain of RP105.
Direct interaction of RP105-MD-1 with TLR4-MD-2
The extracellular localization of the inhibitory effects of the RP105 suggested a mechanistic model involving direct interactions between the RP105-MD-1 and TLR4-MD-2 complexes. We used coimmunoprecipitation techniques to probe the association of these complexes. These complexes coimmunoprecipitated 'bidirectionally' , demonstrating a physical association between TLR4-MD-2 and RP105-MD-1 (Fig. 6 ). As MD-1 failed to associate with TLR4 in the absence of MD-2 (data not shown), the ability of MD-1 to associate with TLR4-MD-2 ( Fig. 6, lanes 2 and 3) suggested the possibility that MD-1 and MD-2 interact directly. Indeed, immunoprecipitation analysis showed the presence of such interactions (Supplementary Fig. 4 online) . Biotin-labeled LPS has been used to demonstrate that LPS binds directly to MD-2, leading to the association of LPS-MD-2 complexes with TLR4 and to TLR4 signaling 29 . Replicating those data, incubation of biotinylated LPS with TLR4-expressing HEK 293 cells allowed for precipitation of TLR4 (and MD-2) only in the presence of MD-2 expression (Fig. 7a) . Notably, coexpression of RP105-MD-1 in this system inhibited LPS-TLR4-MD-2 complex formation (Fig. 7a) , providing direct evidence that RP105-MD-1 inhibits LPS signaling complex formation. The finding that, consistent with published data 30 , no direct interactions between LPS and RP105-MD-1 were demonstrated in this system (Fig. 7b) indicated that RP105-MD-1-mediated interference with LPS signaling complex formation was not due to RP105-MD-1's acting as a 'molecular sink' for LPS. Thus, RP105-MD-1 interacts directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligand.
RP105 is a physiological regulator of cytokine production Although expression studies in cell lines have considerable utility, they also have obvious drawbacks, principally that overexpression may drive nonphysiological interactions and processes. To confirm and extend our findings in transfected cell lines, we examined RP105-deficient mice generated by targeted disruption of exon 3 of RP105 (ref. 25) and backcrossed for more than 10 generations onto the C57BL/6 background. We generated bone marrow-derived DCs by standard techniques 31 from age-matched RP105-deficient mice and wild-type littermate controls. DCs generated from RP105-deficient mice seemed to be phenotypically normal. In particular, flow cytometry showed no differences in DCs generated from RP105-sufficient versus RP105-deficient mice in baseline expression of CD14, TLR4, CD83, CD11c, CD80, CD86 or major histocompatibility complex class II (data not shown). Furthermore, RT-PCR analysis showed no differences in expression of any of the TLRs, MD-1 or MD-2, or the TLR pathway inhibitors IRAK-M, SIGIRR, ST2, Tollip or SOCS1 in such DCs ( Supplementary Fig. 5 online and data not shown).
DCs from RP105-deficient mice produced significantly higher concentrations of proinflammatory cytokines after stimulation with purified Escherichia coli LPS than did DCs from wild-type controls (Fig. 8) . Thus, RP105-mediated suppression of TLR4 signaling is not merely an overexpression artifact in cell lines. In DCs from RP105-deficient mice, there was increased TLR4-driven secretion of the cytokines tumor necrosis factor (TNF), IL-12p70 and IL-6 ( Fig. 8a-c) , whose TLR4-driven production occurs through the signaling adaptor proteins Mal-MyD88, as well as increased secretion of the chemokine IP-10 ( Fig. 8d) , whose TLR4-driven production occurs through a complementary signaling pathway mediated by the TRIF-TRAM adaptor proteins, whose TLR4-driven production occurs through a complementary signaling pathway mediated by the TRIF-TRAM adaptor proteins. RP105-mediated modulation of cytokine production by DCs also showed specificity; for example, CpG (TLR9)-driven cytokine production was similar in DCs generated from RP105-deficient and wild-type mice (Fig. 8e) . There was also RP105-mediated modulation of proinflammatory cytokine production in macrophages; resident peritoneal macrophages from RP105-deficient mice produced significantly higher concentrations of TNF after stimulation with purified E. coli LPS than did macrophages from wild-type controls ( Supplementary Fig. 6 online) We further examined the biphasic dose-response of TNF, IL-12p70 and IL-6 production in DCs from both wild-type and knockout mice (Fig. 8) . Flow cytometry showed that the reduced cytokine production at higher doses of LPS was not associated with greater DC apoptosis (data not shown). Commercial LPS preparations are typically contaminated with lipopeptide ligands for TLR2 (ref. 32) . Such preparations of LPS continued to drive increasing TNF production at higher doses (Fig. 9a) , the very doses at which such preparations drove IL-8 production by HEK 293 cells transfected with TLR2 (data not shown). Notably, stimulation of DCs with these higher doses of commercial LPS preparations led to similar amounts of TNF production by DCs from RP105-deficient and wild-type mice (Fig. 9a) . Indeed, stimulation with combinations of purified TLR4 and TLR2 agonists showed that TLR2 agonists were able to effect functional reversal of RP105-mediated inhibition of TLR4 signaling (Fig. 9b) . These data indicate that, as with many biological agonistic responses, the response to a pure TLR4 ligand is biphasic and can be modified by secondary agonists and that signaling through other TLRs can overcome RP105-mediated modulation of TLR4 signaling.
Other modulators of TLR signaling are themselves regulated by TLR signaling 33 . We used quantitative RT-PCR to examine RP105 expression after LPS stimulation of mouse DCs. TLR4 signaling induced transient upregulation of RP105 mRNA expression along with the downregulation of TLR4 mRNA expression described before 34 ; this result was unaltered by a lack of RP105 expression in such cells ( Supplementary Fig. 7 online) . Despite those findings, preliminary experiments have not demonstrated involvement of RP105 in endotoxin tolerance (data not shown). Notably, LPS stimulation of human DCs induced coordinate downregulation of both TLR4 and RP105 ( Supplementary Fig. 7 online) , adding to the growing body of findings of divergent regulation of TLRs in humans and mice 35 .
Finally, we compared LPS-driven in vivo responses in RP105-deficient and wild-type mice. Notably, RP105-deficient mice produced significantly more TNF in response to low-dose intraperitoneal challenge with E. coli LPS (Fig. 10a) . Furthermore, high-dose LPS challenge led to significant acceleration and amplification of endotoxicity in RP105-deficient mice (Fig. 10b) . Thus, RP105 is a physiological regulator of responses to LPS in primary myeloid cells in vitro as well as in vivo.
DISCUSSION
The studies reported here have shown that RP105, a TLR4 homolog whose expression mirrors that of TLR4 on antigen-presenting cells, is a negative regulator of TLR4 signaling. RP105 specifically inhibited TLR4 signaling when coexpressed in HEK 293 cells. Furthermore, RP105 was a physiological regulator of endotoxin-driven TLR4 signaling in DCs as well as of endotoxicity in vivo.
Although the activation of proinflammatory responses through TLRs is critical for host defense, excessive or inappropriate inflammation can itself be maladaptive. RP105 joins a growing list of molecules that can inhibit TLR signaling. Regulation of TLR expression provides one point of control 2 , as does the complex phenomenon of endotoxin tolerance 36 . Several direct, negative regulators of TLR signaling have also been found, including SIGIRR 33 41 . Among these, RP105 stands out for its apparent specificity for inhibition of TLR4 signaling.
That specificity, together with the structural homologies between RP105 and TLR4, suggested a likely hypothesis for the mechanism of negative regulation of TLR4 signaling by RP105: interference with TLR4 signaling through direct interactions of RP105-MD-1 with the TLR4-MD-2 cell surface signaling complex. Such a model received theoretical support from the apparent lack of signaling in myeloid cells mediated by antibodies to RP105, the finding that RP105-mediated inhibition of TLR4 signaling suppressed both signaling pathways (Mal-MyD88 and TRIF-TRAM) known to be downstream of TLR4 and the finding that RP105-MD-1 was not able to inhibit NF-kB transactivation driven by overexpression of TLR4 signaling intermediates. Such results suggested an upstream, probably extracellular locus for RP105-mediated inhibition. In fact, structure and function analysis of RP105 was consistent with this: the extracellular domain of RP105 was sufficient to effect specific, negative regulation of TLR4 signaling. Finally, coimmunoprecipitation experiments showed direct physical association between RP105-MD-1 and TLR4-MD-2, an association that inhibits binding of LPS to this signaling complex. The exact stoichiometry of RP105-MD-1-MD-2-TLR4 interactions remains to be defined.
The available data suggest that RP105 regulates LPS responses differently in myeloid cells and B cells 6, 13, [25] [26] [27] . The fact that antibodies to RP105 drive B cell proliferation was integral to the discovery of this molecule 6 . B cell proliferation mediated by antibodies to RP105 seems to involve signaling through the Lyn-CD19-Vav complex, along with protein kinase CbI/II and the Erk2-specific MAP kinase kinase MEK 26, 27 . However, RP105 does not seem to signal directly in B cells. As noted above, treatment with antibodies to RP105 did not activate human monocytes and macrophages, failing, for example, to drive proinflammatory cytokine production. As for LPS-driven B cell responses, whereas LPS-induced mouse B cell proliferation is strictly dependent on TLR4, B cells from RP105 knockout mice have reduced LPS-driven proliferative responses as well as diminished humoral immune responses to LPS 25 . It is reasonable to suspect that the dichotomous effects of RP105 on TLR4 signaling in B cells and myeloid cells are due to differential interactions with cell surface molecular partners in these different cell types. Widely differing expression of TLR4 (greater on myeloid cells; barely detectable on B cells 25, 42 ) may provide the key. The formation of multimers by TLR4 seems to be necessary for signaling 29 . Although TLR4-MD-2 would be expected to have a higher affinity for the formation of homodimers than of heterodimers with RP105-MD-1, the data presented here suggest the likelihood that both homo-and heterodimers can additionally form multimers with TLR4-MD-2 complexes. This suggests that when TLR4-MD-2 is highly expressed (for example, on myeloid cells), lower-affinity heterodimeric interactions inhibit TLR4's formation of multimers and signaling. In contrast, when TLR4 is limiting (for example, on B cells), such heterodimeric interactions serve to facilitate further TLR4 recruitment and signaling. The fact that RP105 seems to promote B cell activation while inhibiting DC activation suggests the possibility that overall, immunoregulation by RP105 leads to augmentation of humoral immunity (through effects on B cells) along with concomitant inhibition of cellular immune responses (through effects on DCs and macrophages).
The apparent TLR4 specificity of RP105 raises another issue. Concurrent stimulation of TLR4 and other TLRs is able to reverse RP105-mediated inhibition of TLR4 signaling. Clearly, most microbes that express ligands that stimulate TLR4 signaling also express ligands that stimulate signaling through other TLRs. TLR4 is notable for leading to a more robust and complex response, both in terms of signaling and in terms of subsequent gene expression, than that of the other TLRs 43 . TLR4 may also stand out among the TLRs for its ability to signal in response to a variety of endogenous 'danger signals' 2 . The ability of TLR4 to recognize endogenous heat-shock proteins and extracellular matrix components 'unmasked' by tissue injury suggests the possibility that RP105 may well be of special importance in downmodulation of the injurious inflammatory responses noted in the systemic inflammatory response syndrome and in autoimmune diseases. In this context, it is notable that RP105-deficient mice spontaneously develop splenomegaly with age (data not shown).
Recent renewed mechanistic interest in the innate immune system should lead to the development of new therapeutic approaches to a variety of infectious and autoimmune diseases. The identification here of RP105 as a physiological, endogenous inhibitor of TLR4 signaling would seem to hold similar 'translational' promise.
METHODS
Reagents. Zymosan A and commercial LPS were from Sigma. Highly purified E. coli LPS was generated as described 44 . The synthetic lipopeptide Pam 3 Cys was from EMC Microcollections. CpG (5¢-TCCATGACGTTCCTGATGCT-3¢) was from TriLink Biotechnologies. Recombinant cytokines were from Peprotech. All reagents contacting cultured cells were endotoxin-free to the limits of detection of the limulus amebocyte lysate assay (Bio-Whittaker) at the concentrations used, unless otherwise stated.
Cloning and expression constructs. Human RP105 and MD-1 were cloned from primary human monocytes by RT-PCR. RP105 deletion mutants and epitope-tagged RP105 and MD-1 constructs were generated by PCR. The herpes simplex virus thymidine kinase promoter-driven renilla luciferase reporter plasmid (pRL-TK) was from Promega; the NF-kB-dependent ELAM-1 promoter-driven firefly luciferase plasmid (P-ELAM) has been described 23 . The cDNA encoding TLR4 was from R. Medzhitov (Yale University, New Haven, Connecticut); cDNa encoding MD-2 was from K. Miyake (University of Tokyo, Tokyo, Japan). Plasmids encoding Mal, MyD88, IRAK-1 and TRIF were from K. Fitzgerald (University of Massachusetts, Worcester, Massachusetts). The IkB 'super-repressor' expression plasmid was from R. Hay (University of St. Andrews, St. Andrews, Scotland).
Cell lines. HEK 293 cell lines stably expressing CD14, CD14-TLR4, CD14-TLR2 and TLR4-MD-2 have been described 23, 45 . HEK 293 cells stably expressing RP105-CD14-TLR4 were generated from CD14-TLR4 HEK 293 cells. Transient transfections used PolyFect (Qiagen). Construct expression was quantified by flow cytometry. All cell lines were mycoplasma free.
In vitro stimulation. At 24 h after transient transfection, HEK 293 cells were washed and were stimulated for an additional 24 h. Cell-free supernatants were collected and were assayed for IL-8 production by enzyme-linked immunosorbent assay (ELISA; Pharmingen). For assay of NF-kB-driven luciferase expression 23 , cells were transfected with pELAM (0.5 mg) plus pRL-TK (0.1 mg) plasmids together and were stimulated for 5 h and lysed, and luciferase activity was quantified on a Monolight 3010 luminometer (Pharmingen).
Immunoprecipitation and immunoblots. At 48 h after transfection, HEK 293 cells were washed and lysed. For immunoprecipitation with anti-hemagglutinin (Y-11; Santa Cruz), cell lysates were incubated with antibody, followed by incubation with protein G-Sepharose beads (Zymed). For immunoprecipitation with FLAG monoclonal antibody, cell lysates were incubated with anti-FLAG (M2) affinity gel (Sigma). Immunoprecipitates and lysates were resolved by SDS-PAGE and were electrotransferred onto Immobilon P polyvinyldifluoride membranes (Millipore). After blocking, proteins were detected by probing with unconjugated M2 monoclonal antibody (to FLAG; Sigma), Y-11 rabbit polycolonal antibody (to hemagglutinin; Santa Cruz) and Ab-1 rabbit polyclonal antibody (to MD-1; Oncogene), followed by horseradish peroxidaseconjugated secondary monoclonal antibody (Santa Cruz). LPS labeling and immunoprecipitation with biotinylated LPS were done as described 29 .
Mice. RP105-deficient mice on a C57BL/6 background (more than 10 generations) have been described 25 . Mice were genotyped by PCR and were phenotyped for RP105 surface expression on peripheral blood B cells 25 ( Supplementary Fig. 8 online) . In vivo DC amplification was accomplished by daily intraperitoneal administration of 10 mg of Flt3 ligand (provided by Immunex/Amgen) for 10 d. Mice were housed in a specific pathogen-free facility in high-efficiency particulate-filtered laminar flow hoods with free access to food and water. Animal care was provided in accordance with National Institutes of Health guidelines (Bethesda, Maryland). These studies were approved by the Cincinnati Children's Hospital Medical Center Institutional Animal Care and Use Committee (Cincinnati, Ohio).
Ex vivo stimulation. Mouse bone marrow-derived DCs generated with standard protocols 31 were stimulated for 24 h. Cell-free supernatants were collected and were assayed by ELISA for TNF (Becton Dickinson), IL-12p70, IL-6 and IP-10 (R&D Systems). RP105, TLR4, IRAK-M, SIGIRR, Tollip and ST2 mRNA expression was analyzed by quantitative RT-PCR in bone marrowderived DCs before and after stimulation with 10 ng of purified E. coli K235 LPS. PCR (LightCycler; Roche) used the following primers: RP105, 5¢-AGTCTCCTCCCCATCTTGTCC-3¢ and 5¢-GATAGCGTCACATCGGAGA GC-3¢; TLR4, 5¢-CATCCAGGAAGGCTTCCACA-3¢ and 5¢-GGCGATACAATT CCACCTGC-3¢; IRAK-M, 5¢-GAGAATTGCTCTGGTCCTGGG-3¢ and 5¢-CACCTCAAGTGGGAAGCTGG-3¢; SIGIRR, 5¢-GGCCCCTAATTTCCTTTC CC-3¢ and 5¢-CATGGAGGCTGAAGTGGCTT-3¢; Tollip, 5¢-TGGACCCACAT CACCATCC-3¢ and 5¢-GTTGGCATCAGGACCACAGG-3¢; ST2, 5¢-GGCTCT CACTTCTTGGCTGATG-3¢ and 5¢-GCCAGACAGTCATATTCCAGGG-3¢; and b-actin, 5¢-GGCCCAGAGCAAGAGAGGTA-3¢ and 5¢-GGTTGGCCTTAGGGT TCAGG-3¢.
In vivo stimulation. Mice 6-8 weeks of age were challenged intraperitoneally with 25 mg of purified E. coli K235 LPS. Then, 1 h later, serum was collected. TNF concentrations were measured by ELISA. For endotoxicity studies, mice were challenged intraperitoneally with 8 mg/kg of purified E. coli K235 LPS. Mice were assigned scores for clinical endotoxicity by an investigator 'blinded' to mouse genotype, using a quantitative scale integrating four cardinal signs of systemic toxicity 46 (piloerection, ocular discharge, lethargy and diarrhea; each assigned a score from 0 to 3).
Human leukocytes. Peripheral blood mononuclear cells were isolated from healthy volunteers by Ficoll-Hypaque sedimentation. Monocytes were purified by countercurrent elutriation from peripheral blood mononuclear cells isolated by leukapheresis 47 . Purified monocytes were differentiated into DCs by standard techniques using IL-4 and granulocyte-monocyte colony-stimulating factor. RP105 and TLR4 mRNA expression was analyzed by quantitative RT-PCR in human monocyte-derived DCs with the following primers: RP105, 5¢-TCAGTGCTGCCAATTTCCC-3¢ and 5¢-CTGCAGCAGTCAGAAGCCTCT-3¢; TLR4, 5¢-AGTTTCCTGCAATGGATCAAGG-3¢ and 5¢-GGACCGACACAC CAATGATG-3¢; and ubiquitin, 5¢-CACTTGGTCCTGCGCTTGA-3¢ and 5¢-CAATTGGGAATGCAACAACTTTAT-3¢. These studies were approved by the Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine institutional review boards (Cincinnati, Ohio).
Flow cytometry. Surface and intracellular protein expression by HEK 293 cells was quantified by flow cytometry techniques that have been described 48 . A FACSCalibur and CellQuest Software (Becton Dickinson) were used for flow cytometry. At least 20,000 events were acquired for each data point.
Phylogenetic and domain analysis. Sequences were aligned with the ClustalW 49 and Pileup 50 programs. MEMSAT 51 , SOSUI 52 and SABLE (http://folding. chmcc.org/.; volume 2004) software were used for prediction of transmembrane boundaries.
Statistical analysis. Data were analyzed with the unpaired Student's t-test or with analysis of variance with post-hoc analysis by Student's t-test or Fisher's protected least-significant difference test, as appropriate.
Note: Supplementary information is available on the Nature Immunology website.
